藥石科技(300725.SZ):上半年淨利同比增26.08%至8733.62萬元
格隆匯 8 月 26日丨藥石科技(300725.SZ)披露2020年半年度報告,報告期內,公司實現營業收入4.6億元,較上年同期增加58.17%;實現營業利潤9612.15萬元,較上年同期增加26.05%;實現利潤總額1億元,較上年同期增加27.26%;2020年半年度實現歸屬於上市公司股東的淨利潤8733.62萬元,較上年同期增加26.08%;扣除非經常性損益的淨利潤8191.62萬元,較上年同期增加25.41%。報告期內,股權激勵費用攤銷對公司淨利潤影響約2225萬元。
受新冠肺炎疫情影響延遲復工,公司一季度收入增速有所放緩,公司通過提升經營管理效率,有效組織公司整體復工復產,二季度實現了在銷售規模不斷擴大並進一步提升了市場競爭力,確保了公司業績持續穩定增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.